2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Imaging, Molecular Testing, Treatment Considerations, Therapy Sequence, Biological Therapies, Transplantation, Non-Biological Therapies, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Microbiome, Clinical Practice (Health Services and Quality), Clinical Guidelines, Value, Diseases, Bone Marrow Failure Syndromes, Aplastic Anemia, Immunology, GVHD, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Research, AML, MDS, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

6040 CMV-specific T-cell immunity measured by flowspot assay predicts safe discontinuation of letermovir in pediatric allogeneic hematopoietic stem cell transplantation

Xiaoyan Zhang, Xia Chen2, yang wan3, Lipeng Liu4, Luyang Zhang5, Xiaolan Li6, Xiaofan Zhu, MD7, Fang Liu8
1 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
2 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
3 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
4 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
5 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
6 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
7 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
8 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China

Introduction

CMV reactivation contributes significantly to morbidity following allogeneic hematopoietic stem cell transplantation (allo-HSCT) in children. The reconstitution of CMV-specific T-cell-mediated immunity (CMI) is a key determinant of viral control, and CMI assessment is increasingly employed to individualize the duration of antiviral prophylaxis.

The FlowSpot assay quantifies CMV-specific T-cell responses by interferon-γ (IFN-γ) capture on fluorescent microspheres followed by flow cytometric detection. This method shows strong correlation with the conventional enzyme-linked immunospot (ELISpot) assay while offering reduced cost and shorter turnaround time. Its clinical utility in the pediatric post-transplant setting, however, has not been evaluated.

Here, we examined CMV-CMI reconstitution measured by FlowSpot in a uniformly managed pediatric allo-HSCT cohort to determine the influence of graft type, underlying disease, and age on immune recovery, and to assess the safety of CMI-guided letermovir discontinuation.

Methods

Fifty pediatric allo-HSCT recipients (median age 11 years, range 3–17; 52% male) transplanted between November 2025 and April 2026 were included. Underlying diagnoses were AML (n=17), aplastic anemia including SAA and VSAA (n=14), ALL (n=9), MDS (n=7), CML (n=1), mixed phenotype acute leukemia (n=1), and other (n=1). Graft sources comprised UCBT (n=31), haploidentical PBSCT (n=12), matched sibling donor HSCT (n=6), and autologous cord blood transplantation (n=1).

All patients received letermovir beginning at day +7. FlowSpot testing was initiated at 3 months post-transplant. Letermovir was discontinued upon identification of a positive CMV-CMI response, or at day +200 if CMI remained absent. No patient developed CMV end-organ disease or clinically significant CMV infection.

The FlowSpot-CMV assay (Beijing BFR Gene Diagnostics) was performed as described. A signal ratio (sample/negative control) ≥2.0 defined a positive CMV-CMI response. Time to CMI reconstitution was calculated from the date of transplant to the first positive result.

Results

CMV-CMI was detected in 31 of 50 patients (62.0%) at a median of 5.0 months post-transplant (range 2.9–12.2). Among these responders, 71% achieved CMI within 6 months. The median signal ratio in positive tests was 6.9 (range 2.0–681.9).

CMI reconstitution differed markedly by graft type. All 6 MSD-HSCT recipients achieved CMI at a median of 3.5 months (range 2.9–3.9) with a median signal ratio of 56.9. Among haploidentical PBSCT recipients, 8 of 12 (66.7%) responded at a median of 4.7 months (range 3.1–9.3; median ratio 11.3). UCBT recipients showed the lowest rate (17/31, 54.8%) and the longest time to reconstitution (median 5.6 months, range 3.4–12.2; median ratio 6.5). The single autologous transplant recipient did not develop CMI.

By diagnosis, CMI reconstitution rates were 70.6% (12/17) for AML, 71.4% (5/7) for MDS/RCC, 55.6% (5/9) for ALL, and 42.9% (6/14) for AA/SAA/VSAA. Median time to CMI in AA/SAA/VSAA and MDS/RCC was 3.6 months compared with 5.6 months for AML. CMI reconstitution rates by age group were 83.3% (0–5 years; n=6), 68.4% (6–10 years; n=19), 45.0% (11–15 years; n=20), and 80.0% (≥16 years; n=5). Rates did not differ by sex (male 61.5% vs. female 62.5%).

Serial testing (≥2 tests) was performed in 11 patients (22%). Seroconversion occurred in 4 patients, 6 remained persistently negative, and 1 had a transient positive response with subsequent reversion.

Conclusions

CMV-CMI reconstitution after pediatric allo-HSCT is strongly influenced by graft type: MSD-HSCT recipients consistently achieve early CMI, whereas more than 45% of UCBT recipients fail to do so. AA/SAA/VSAA and age 11–15 years are additional risk factors for impaired CMI recovery. CMI-guided letermovir discontinuation was not associated with CMV reactivation or disease in this cohort. These findings define patient subgroups at highest risk for delayed immune reconstitution who may benefit from extended prophylaxis, and support the rationale for prospective, CMI-directed CMV management trials in pediatric HSCT.

Xiaoyan Zhang: No relevant conflicts of interest to declare.